Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
80 participants
INTERVENTIONAL
2023-09-07
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* Is the new drug well tolerated and safe?
* Can the new drug protect and preserve kidney functions when is added to standard therapy?
Researchers will compare the following groups to see how the new drug is tolerated and what effect to preserve kidney tissue has:
* Group A: Standard treatment + ALE.F02 low dose infusions
* Group B: Standard treatment + ALE.F02 high dose infusions
* Group C: Standard treatment + ALE.F02 maximum dose infusions
* Group D: Standard treatment + placebo infusions (inactive substance)
The Treatment period will consist of 24 weeks beginning on Day 1, during which time participants will receive 13 infusions of the study medicine, along with standard therapy for kidney inflammation due to AAV. During the treatment period, participants will have the following assessments:
* A brief physical examination focusing on their skin any pre-existing medical conditions that you have.
* Collection of blood and urine samples for routine safety tests and to assess renal function.
* Collection of blood samples:
* To measure the amount of study medicine in their blood. This is called pharmacokinetics (PK) and it is tested to see how study medicine enters, moves through, and exits the body.
* To test for antidrug antibodies (ADA). To check if their body create antibodies against the study medicine, as this could reduce its effect.
* To measure biomarkers. Biomarkers are specific compounds in the body (can be protein, hormones, or genetic molecules) that indicate normal or abnormal processes taking place in your body and may be a sign of an underlying condition or disease (for example glucose levels are used as biomarker in managing diabetes). They are used to see how well the body responds to a treatment for a disease or condition.
* Collection of urine to measure urine markers of vasculitis/inflammation called biomarkers.
* Urine pregnancy test. A urine pregnancy test is a quick medical test that can tell if a woman is pregnant or not by checking for a hormone which is produced during pregnancy, usually in the urine.
* Chest High Resolution Computed Tomography (HRCT) scan to check whether they have vasculitis affecting their lungs. A CT scan uses special x-ray equipment to take detailed pictures of body tissues and organs to diagnose and monitor conditions in various parts of the body. For the CT scan, they will need to lie still on a table. At Week 24 a second lung CT scan will be performed for participants whose initial scan showed lung vasculitis to see whether your lung vasculitis is getting better or ongoing/worse.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
NCT03373461
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT02949128
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
NCT03298698
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)
NCT00193648
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard treatment + ALE.F02 low dose infusions
Standard treatment + ALE.F02 low dose infusions
ALE.F02
ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.
Rituximab
Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
GlucoCorticoid
Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
Cyclophosphamid
Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
Immunosuppressive Agents
Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
Standard treatment + ALE.F02 high dose infusions
Standard treatment + ALE.F02 high dose infusions
ALE.F02
ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.
Rituximab
Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
GlucoCorticoid
Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
Cyclophosphamid
Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
Immunosuppressive Agents
Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
Standard treatment + placebo infusions (inactive substance)
Standard treatment + placebo infusions (inactive substance)
Rituximab
Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
GlucoCorticoid
Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
Cyclophosphamid
Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
Placebo
Drug product that will contain no active ingredient
Immunosuppressive Agents
Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
Standard treatment + ALE.F02 maximum dose infusions
Standard treatment + ALE.F02 maximum dose infusions
ALE.F02
ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.
Rituximab
Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
GlucoCorticoid
Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
Cyclophosphamid
Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
Immunosuppressive Agents
Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALE.F02
ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.
Rituximab
Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
GlucoCorticoid
Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
Cyclophosphamid
Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
Placebo
Drug product that will contain no active ingredient
Immunosuppressive Agents
Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must be willing and able to comply with the study requirements and give informed consent for participation in the study;
3. Must be willing to have a renal biopsy procedure performed no later than prior to study drug administration at the Week 6 Visit; alternatively, a historical biopsy performed up to 45 days prior to the initiation of study drug administration is considered acceptable;
4. Have been newly diagnosed with RPGN within 45 days prior to the initiation of study drug treatment, as demonstrated by the following: - Evidence of loss of renal function with an eGFR of ≤50 mL/min/1.73 m2 and ≥10 mL/min/1.73 m2; and - History of proteinuria of any degree AND/OR hematuria that is temporally associated with the presenting episode of illness and supports the diagnosis of RPGN. Note: The hematuria may be represented by the presence of eumorphic or dysmorphic red blood cells (RBCs) and/or RBC casts. Patients with extrarenal manifestations of ANCA which started prior to RPGN should be discussed with the Medical Monitor and the Sponsor.
5. Are suspected of having RPGN attributed to AAV at Screening based on clinical laboratory diagnostic criteria, including a positive test for an ANCA, ie, anti-myeloperoxidase (MPO) or anti-proteinase 3 (PR3);
6. Have a body weight of ≤130 kg;
7. Female patients must not be pregnant or lactating at Screening and 1 of the following conditions must apply: - Is a female of childbearing potential and agrees to use a highly effective method of birth control during their participation in the study and for at least 5 half-lives or a minimum of 30 days after the last dose of study drug, or as recommended in the Summary of Product Characteristics (SmPC) of any authorized AxMP given as part of background standard of care (SOC) therapy, whichever is longer; or - Is a female of nonchildbearing potential.
8. Female patients must agree not to donate ova for 6 months after the last dose of study drug or as recommended in the SmPC of any authorized AxMP given as part of background SOC therapy, whichever is longer;
9. Male patients must agree to use contraception, in the form of either sexual abstinence or a condom, during their participation in the study and for 90 days after the last dose of study drug or as recommended in the SmPC of any authorized auxiliary medicinal product (AxMP) given as part of background SOC therapy, whichever is longer; and
10. Male patients must agree to abstain from sperm donation during their participation in the study and for 90 days after the last dose of study drug or as recommended in the SmPC of any authorized AxMP given as part of background SOC therapy, whichever is longer.
Exclusion Criteria
2. Have a positive serology test for anti-glomerular basement membrane antibodies;
3. Have evidence of active or latent tuberculosis (TB) determined by a positive (not indeterminate) QuantiFERON®-TB Gold test (or equivalent). In countries where QuantiFERON®-TB Gold test (or equivalent) is not available, radiological criteria, including chest X-ray or computed tomography scan, may alternatively be used;
4. Have a chronic infection that could be exacerbated by RPGN or SOC therapy for RPGN;
5. Have active hepatitis B, hepatitis C, or HIV infection;
6. Have taken any prohibited medications.
7. Have received a course of SOC therapy which exceeds a high-dose prolonged regimen of treatment of ANCA RPGN, such as \>3000 mg of IV methylprednisolone-equipotent glucocorticoids, or \>1 mg/kg/day of oral glucocorticoids (prednisone equivalent) for \>14 days (doses are provided as a guidance for assessment of intensity; patients who received high-dose glucocorticoids should be discussed with and approved by the Medical Monitor and the Sponsor); Note: A course of systemic glucocorticoids attributed to extrarenal manifestation of ANCA should not be included in the assessment of Exclusion Criterion 7 and such occasions should be discussed with the Medical Monitor and the Sponsor. IV methylprednisolone administered as pre-medication for rituximab may be considered as prophylaxis of a potential hypersensitive response to rituximab. This pre-medication is allowed during the course of the study and will not account in the total dose calculation of the IV glucocorticoids threshold of 3000 mg at Screening for eligibility assessment.
8. Have been treated or planned to be treated with avacopan;
9. Have poor venous access;
10. Have participated in an investigational drug or device study and received investigational therapy \<30 days or 5 half lives, whichever is the greater, prior to the first dose of study drug. For biological investigational drugs, the exclusionary period may not be \<90 days prior to the first dose of study drug;
11. Have a history of psoriasis, AD, excessively dry skin or recurrent conjunctivitis that has required treatment prescribed by a physician, scleroderma, vitiligo, or any other active autoimmune dermatological disorder, with the exception of dermatological disorders or skin rashes that are attributable to, or known to be associated with, the underlying diagnosis of AAV, which shall not be exclusionary;
12. Have a diagnosis of systemic lupus erythematosus-AAV overlap syndrome;
13. Have a diagnosis of eosinophilic granulomatosis with polyangiitis;
14. Have evidence of uncontrolled respiratory, cardiac, hepatic, endocrine, central nervous system, or renal disease, unrelated to RPGN or AAV, that the PI believes cannot be readily brought under control, or any other medical condition that in the opinion of the PI renders the patient unsuitable for enrollment and could prevent the successful completion of the study;
15. Have received a live vaccine within 30 days prior to Screening;
16. Have received any vaccine within 7 days of the first dose of study drug other than against influenza or pneumococcal infection;
17. Are employed by the PI or the study site, have direct involvement in the proposed study or other studies under the direction of that PI, or are a family member of the PI or study site personnel;
18. Have not recovered from AEs and/or complications from major surgery prior to the first dose of study drug; Note: The PI should consult with the Medical Monitor and Sponsor to determine if ongoing, significant complications from major surgery are exclusionary.
19. Have active or known history of alcohol or substance abuse within 1 year prior to Day 1/Randomization or have a positive urine drug screen for drugs of abuse at Screening;
20. Have been diagnosed within the preceding 5 years with a malignant neoplastic disease, other than locally invasive cutaneous squamous or basal cell carcinoma;
21. Have alveolar haemorrhage with hypoxia defined by an oxygen saturation \<85% or that requires the use of invasive or noninvasive ventilatory support;
22. Have undergone dialysis within 7 days prior to Screening;
23. Have undergone therapeutic plasma exchange within 7 days prior to the first dose of study drug; or
24. Have known hypersensitivity to the study drug or any of the excipients used in the formulation of the study drug.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alentis Therapeutics AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vseobecna fakultni nemocnice v Praze
Prague, , Czechia
Institut klinicke a experimentalni mediciny
Prague, , Czechia
Aalborg University Hospital
Aalborg, , Denmark
Aarhus University Hospital
Aarhus, , Denmark
Rigshospitalet
Copenhagen, , Denmark
Odense University Hospital
Odense, , Denmark
Centre Hospitalier Boulogne sur Mer
Boulogne-sur-Mer, Cedex, France
CHU Bordeaux - Hopital Pellegrin
Bordeaux, , France
CHRU de Brest - Hopital de la Cavale Blanche
Brest, , France
CHU Grenoble-Alpes - Hopital Michallon
La Tronche, , France
CHU de Nantes - Hotel-Dieu
Nantes, , France
CHU de Nimes
Nîmes, , France
AP-HP Hopital Pitie-Salpetriere
Paris, , France
AP-HP Hopital Cochin
Paris, , France
CHU de Toulouse - Hopital Rangueil
Toulouse, , France
Centre Hospitalier de Valenciennes
Valenciennes, , France
Charite Universitaetsmedizin Berlin
Berlin, , Germany
Universitaetsklinikum Koeln (AoeR)
Cologne, , Germany
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, , Germany
Universitaetsklinikum Essen
Essen, , Germany
Medizinische Hochschule Hannover (MHH)
Hanover, , Germany
Universitaetsklinikum Leipzig
Leipzig, , Germany
Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
Lübeck, , Germany
Klinikum der Ludwig-Maximilians-Universitaet Muenchen
München, , Germany
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
Bergamo, , Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, , Italy
IRCCS Ospedale San Raffaele
Milan, , Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, , Italy
APSS Ospedale Santa Chiara di Trento
Trento, , Italy
Fundacio Puigvert
Barcelona, , Spain
Hospital Universitari de Bellvitge
Barcelona, , Spain
Hospital Universitari Arnau de Vilanova
Lleida, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Regional Universitario de Malaga
Málaga, , Spain
Linkoping University Hospital
Linköping, , Sweden
University Hospital of Umea
Umeå, , Sweden
Kantonsspital Baden AG
Baden, , Switzerland
Inselspital, Universitaetsspital Bern
Bern, , Switzerland
Kantonsspital St. Gallen
Sankt Gallen, , Switzerland
Hôpital Fribourgeois-Freiburger Spital
Villars-sur-Glâne, , Switzerland
Ankara Etlik City Hospital
Ankara, Keçiören, Turkey (Türkiye)
Marmara University Medical Faculty Hospital
Istanbul, , Turkey (Türkiye)
Kocaeli University Medical School - Internal Medicine - Nephrology
Kocaeli, , Turkey (Türkiye)
Erciyes University Faculty of Medicine
Melikgazi, , Turkey (Türkiye)
Queen Elizabeth Hospital Birmingham
Birmingham, , United Kingdom
Cambridge University - Addenbrooke's Hospital
Cambridge, , United Kingdom
Royal Liverpool University Hospital
Liverpool, , United Kingdom
Imperial College Healthcare NHS Trust
London, , United Kingdom
Royal Preston Hospital
Preston, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-502184-38
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1286-9095
Identifier Type: OTHER
Identifier Source: secondary_id
ALE.F02.03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.